oligonucleotide antisense therapy for spinocerebellar ataxia (Exicure)

N/A

Report date: 2025/01/26 17:31:44
NME

Base Information

Drug Nameoligonucleotide antisense therapy for spinocerebellar ataxia (Exicure)
Drug Alias NameATXN Gene Inhibitor (Exicure)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionAtaxin-3 inhibitors
TargetsAtaxin-3
Therapy Area/IndicationsSpinocerebellar Ataxias
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesExicure Inc
China Registration ClassN/A

Develop Information

Active CompaniesExicure Inc
Inactive CompaniesN/A
Active IndicationsSpinocerebellar Ataxias
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A